RxDoctor Payments DataLook up a doctor →

Luis Rivera Colon, MD

Internal Medicine · Rio Piedras, PRNPI 1376608984

Payments from drug & device makers

$74,118in general payments, 2019–2025

Across 541 payments — averaging $137.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$46K
  • Eli Lilly$9K
  • AstraZeneca$5K
  • Merck$5K
  • Sanofi-aventis U.S. LLC$3K
  • Boehringer Ingelheim$2K
  • plus $6K from 18 others
$543,461in research payments, 2019–2025

Across 54 payments — averaging $10,064 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$431K
  • Novo Nordisk AS$99K
  • Eli Lilly$13K

What the payments were for

  • Consulting fees$5,45826%
  • Speaking & faculty fees$2001%
  • Travel & lodging$1311%
  • Food & beverage$14,97172%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,118 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,484
Medicare patients
26
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol329$246,196
Trijardy XrEmpaglifloz/Linaglip/Metformin278$220,762
JardianceEmpagliflozin178$149,170
Xigduo XrDapaglifloz Propaned/Metformin176$133,468
TrulicityDulaglutide97$105,787
GlyxambiEmpagliflozin/Linagliptin112$94,422
OzempicSemaglutide94$93,306
Synjardy XrEmpagliflozin/Metformin Hcl98$67,018
EliquisApixaban78$48,720
SynthroidLevothyroxine Sodium555$44,616
XareltoRivaroxaban48$41,180
SynjardyEmpagliflozin/Metformin Hcl53$33,464
MounjaroTirzepatide20$21,460
LantusInsulin Glargine,hum.Rec.Anlog204$20,899
Lantus SolostarInsulin Glargine,hum.Rec.Anlog196$19,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTrijardy Xr, Jardiance, Glyxambi, Synjardy Xr, Synjardy$1,674$576,476741 claims
AstraZenecaFarxiga, Brilinta, Symbicort$4,688$254,370354 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin N$957$145,244295 claims
Novo NordiskOzempic$1,286$93,30694 claims
PfizerEliquis$75$48,72078 claims
AbbVieSynthroid$114$44,616555 claims
Johnson & JohnsonXarelto$976$41,18048 claims
Sanofi-aventis U.S. LLCLantus$2,771$20,899204 claims
MerckJanuvia$4,673$19,09718 claims
GSKBreo Ellipta$247$5,79314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Rio Piedras

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →